Children report severe pain after T&A -particularly in the first 24 hours post-operatively (Idvall 2005). They also show increased levels of fear and anxiety, avoidance behaviors related to further healthcare, and somatic (other physical) symptoms after an encounter with significant levels of pain (AAP 2001). Additionally, inadequate pain management has been found to increase morbidity and mortality rates in post-operative patients of all ages (EAU 2003) .
Clinical practice has not changed significantly, despite the development of reliable pediatric pain measurement scales and the demonstrated safety and efficacy of numerous analgesics in children (Liossi 2006). Although morphine is most frequently used to treat post-operative pain in adults, it is less often prescribed for children recovering from surgery (US Dept of VA 2006). Notably, the US Food and Drug Administration has recently identified the use of morphine in the pediatric population as a research priority, highlighting the need for evidence that can guide clinical practice to achieve optimal pain control in children (NIH 2006 ).
There are a number of barriers, related both to the clinical case and to a lack of high quality evidence in this population, that conspire to prevent adequate pain management in children. Clinicians may lack confidence when it comes to selecting the most appropriate (of the many) pediatric pain measurement scales for their setting (Chambers 1999). Clinicians may also be unaware of evidence supporting the use of opioid and non-opioid analgesics, adjuvant medications, and non- . Finally, research has shown that pediatric pain measurement is most reliable when self-reported (Chambers 1999). Parents and clinicians consistently under-estimate children's pain levels compared to children's own rating, potentially leading to under-dosing of analgesia (Chambers 1998).
A systematic review of the effects of analgesics for post-operative pain in children who have undergone a T&A will increase awareness and understanding of the factors associated with pediatric pain management, supported by the most recent findings available, to improve pain management in this group of patients.
O B J E C T I V E S
To assess the effectiveness of analgesics for management of postoperative pain in children who have undergone a tonsillectomy or adenoidectomy, or both. The questions to be addressed are: 
M E T H O D S Criteria for considering studies for this review
Types of studies Double-blind, randomised controlled trials (RCTs) that have been published fully in a journal will be considered for inclusion, but not thus published only as abstracts.
Types of participants
Children aged one to 16 years (inclusive) who have undergone a tonsillectomy or adenoidectomy, or both, in an outpatient or inpatient setting.
Types of interventions
Interventions of interest include any type of analgesics, administered by any route, dosage, and schedule, pre-, peri-or postoperatively for tonsillectomy or adenoidectomy, or both. Specific analgesics, alone or in combination, administered for the control of post-operative pain management will be included. Steroids will not be included in this review as they have been reviewed for participants like these in another Cochrane Review (Steward 2003).
Types of outcome measures Primary outcomes
Pain intensity and pain relief: as measured by validated paediatric pain scales that may include a Visual Analog Scale (VAS), Faces Pain Scale, Color Analog Scale (CAS), and categorical scales. Ideally, pain will be assessed by patients, but if no other outcome is available , observer assessed pain will be included.
Secondary outcomes
Any reported adverse events. Use of rescue analgesia will be taken as a secondary measure of pain relief.
Search methods for identification of studies Electronic searches
A search strategy will be developed for use in MEDLINE, and revised appropriately for other databases, in cooperation with the Cochrane Pain, Palliative Care and Supportive Care Cochrane Review Group. The search strategy will combine the subject search with phases 1 and 2 of the Cochrane Sensitive Search Strategy for RCTs as published in Appendix 5c in the Cochrane Handbook (Higgins 2009). The subject search will use a combination of controlled vocabulary and free text terms based on the search strategy for MEDLINE via OVID which can be seen in Appendix 1. 
Searching other resources
The reference lists of eligible trials and previous systematic reviews generated by the searches outlined above will be reviewed. The search strategy will attempt to identify all relevant studies irrespective of language. Non-English papers will be assessed through selective translation by a native speaker where possible. Translations of full texts will be conducted if deemed necessary.
Data collection and analysis

Selection of studies
Two review authors (DOM , PW) will screen the titles and abstracts of retrieved records to identify records likely to meet the inclusion criteria. Full text copies of records initially deemed eligible for inclusion will be obtained for review. All review authors will assess full text reports and determine inclusion or exclusion of the trials, with group discussion for arbitration and resolution if there is uncertainty or disagreement.
Data extraction and management
Two review authors (of DOM, PW, JC) will independently conduct data extraction using a data extraction form. The third review author will be consulted for resolution if there is disagreement . RevMan will be used for statistical analysis. DOM will enter data into RevMan and this will be checked by the other authors.
Assessment of risk of bias in included studies
Two review authors (DOM, JC) will independently assess the methodological quality of included studies. Another review author (PW) will be consulted for arbitration and resolution if there is uncertainty or disagreement. The risk of bias in included studies will be assessed as described in Chapter 8 of the Cochrane Handbook (Higgins 2009). The risk of bias data will be presented in tables and figures on the low to high scales as recommended in Cochrane Handbook. The methodology of each trial will be assessed for:
• sequence generation • allocation concealment • blinding (of participants and outcome assessors)
• incomplete outcome data (covering drop-outs and ITT analysis)
• selective reporting of outcomes • other possible sources of bias (including baseline differences and trial funding)
Measures of treatment effect
Summary statistics for continuous data will be reported as weighted mean difference or standardized mean difference. Summary statistics for dichotomous data will be reported as relative risk (RR). Number needed to treat (NNT) or number needed to harm (NNH) will be calculated.
Dealing with missing data
If more than 20% of the data are data missing from a study, data from that study will be excluded from meta-analysis.
Assessment of heterogeneity
The presence of heterogeneity will be determined with visual examination of forest plot(s) generated from meta-analysis of studies initially considered appropriate for pooling. The degree of statistical heterogeneity will be assessed based on the value of I 2 from meta-analysis and, if present, explanations explored through subgroup or sensitivity analysis (or both), quality control checks of data extraction and data entry, and reviewing of the clinical and methodological aspects of the trials. 
W H A T ' S N E W
C O N T R I B U T I O N S O F A U T H O R S
DOM: helped draft the original protocol and approved the fi nal protocol; for the full review he will search for trials, screen titles and abstracts of retrieved records, enter citations into RevMan, select which trials to include, assess the risk of bias of included studies, extract data from trials, enter data into RevMan, decide which analyses to conduct, interpret the analysis, draft the final review , and coordinate future updates of the review .
PW: helped draft the original protocol and approved the final protocol; for the full review he will screen titles and abstracts of the retrieved records, extract data from trials, interpret the analysis, and edit the final review.
JC: approved the final protocol; for the full review s he will assess the risk of bias of included studies, extract data from trials, and e dit the final review.
